Abstract
SynopsisWhen bone marrow (BM) is taken, cells in suspension are accessible to antibodies. BM transplantation is therefore an ideal situation for using monoclonal antibodies in therapy. These applications include prevention of graft versus host disease by eliminating T cells from allogeneic BM marrow, and the elimination of residual malignant cells from autologous bone marrow. Me Ab-s are currently tested for the removal of residual leukaemic cells in the common form of acute lymphoblastic leukaemia (ALL) and in thymic ALL. Encouraging experiments also indicate that the removal of B leukaemias/lymphomas from the BM will also be feasible.The review summarises the various ways Ab-s can damage coated ‘unwanted’ cells (opsonisation, complement mediated lysis, and Ab-s coupled to toxins), and the principles for selecting Me Ab-s for BM transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
